Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.


Polio Vaccine Resource Center

Poliovirus is a member of the enterovirus subgroup, family Picornaviridae. There are three poliovirus serotypes (P1, P2, and P3). Immunity to one serotype does not produce significant immunity to the other serotypes.

Polio, or poliomyelitis, is a highly infectious viral disease, which mainly affects young children.  Poliovirus is spread person-to-person via fecal-oral route, and less frequently, via oral-oral route. The virus enters through the mouth, and primary multiplication of the virus occurs at the site of implantation in the pharynx and gastrointestinal tract. The virus is usually present in the throat and in the stool before the onset of illness. One week after onset, there is less virus in the throat, but virus continues to be excreted in the stool for several weeks. The virus invades local lymphoid tissue, enters the bloodstream, and then may infect cells of the central nervous system. Replication of poliovirus in motor neurons of the anterior horn and brain stem results in cell destruction and causes the typical manifestations of poliomyelitis.

Most people infected with poliovirus are asymptomatic. When symptoms are present, they usually last less than a week and may include influenza-like illness, upper respiratory tract infection, and/or gastrointestinal disturbances.  In a very small proportion of cases in children (<1%), the disease causes paralysis, which can be permanent, and even lead to death.

Persons infected with poliovirus are most infectious from 7 to 10 days before and after the onset of symptoms, but poliovirus may be present in the stool for 3 to 6 weeks after acute infection.  It can be transmitted even if the infected person is asymptomatic.

There is no cure for polio.  Treatment is symptomatic.  Polio can only be prevented by immunization. There are two types of vaccine that can prevent polio: inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV).  Since 2000, in the United States, only Inactivated Poliovirus Vaccine Inactivated, trade name, IPOL® has been available. 

IPV is indicated for active immunization of infants, children, and adults for the prevention of poliomyelitis caused by poliovirus serotypes P1, P2, and P3. A primary series of IPV consists of three doses with routine administration recommendations at ages 2 months, 4 months, and 6-18 months. A booster dose is recommended between 4-6 years of age.

There are three combination pediatric vaccines that contain inactivated polio vaccine available in the United States – KINRIX, PEDIARIX, and Pentacel®.

Resource Center

You will find below all of the resources you will need about the polio vaccine. More will be added as they are published or released.

Information Paper Date
Poliomyelitis and Poliovirus Vaccine July 10, 2018
Standing Orders Date
Inactivated Polio Vaccine (IPV) (Pediatric)
June 2022
Inactivated Polio Vaccine (IPV) (Adult)
June 2022
Vaccine Information Statements (VIS) Date
Polio Vaccine: What You Need to Know
Aug. 6, 2021
Your Child’s First Vaccines: What You Need to Know
Oct. 15, 2021
Manufacturer Package Inserts Date
June 2, 2022
Nov. 23, 2022
April 26, 2023
Oct. 21, 2022
July 21, 2022
April 12, 2023
Advisory Committee on Immunization Practices (ACIP) Recommendations Date
Polio Vaccine
Aug. 7, 2009

You also may be interested in...

Fractional-Dose Inactivated Poliovirus Vaccine Campaign — Sindh Province, Pakistan, 2016


Because of the limited global stock of inactivated polio vaccine(IPV), fractional-dose intradermal IPV (fIPV), which is one fifth of the full intramuscular dose, has been developed and is being used for polio vaccination activities. However, there are operational challenges related to the use of an intradermally injected vaccine.

Progress Toward Poliomyelitis Eradication — Pakistan, January 2016–September 2017


During January 2016–September 2017, wild poliovirus type 1 cases in Pakistan decreased 45% compared with the same period during 2015–2016. Pakistan remains one of three countries, along with Afghanistan and Nigeria, where wild poliovirus transmission has never been interrupted.

Progress Toward Poliomyelitis Eradication — Afghanistan, January 2016–June 2017


The number of wild poliovirus type 1 cases reported in Afghanistan has declined yearly since 2014, indicating continued progress toward eradication.

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States

Page 2 of 2 , showing items 16 - 19
First < 1 2 > Last 
Last Updated: May 23, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery